GlassScriptPhysician profile
Samuel W Raborn
NPI 1346271913
$3,888.77
in general payments reported to CMS, 2019-2025
31 companies · $990 in 2025
The $990 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $267 · 2021: $446 · 2022: $450 · 2023: $861 · 2024: $875 · 2025: $990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,626 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,626.26 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $670.07 | 2021-2025 | |
| Lilly USA, LLC | $607.85 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $464.40 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $365.92 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.16 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $191.98 | 2020-2025 | Airsupra |
| Astellas Pharma US INC | $189.01 | 2023-2025 | Veozah |
| Abbvie INC. | $160.69 | 2021-2025 | |
| Exact Sciences Corporation | $126.12 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $111.02 | 2020-2025 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $93.18 | 2020-2021 | |
| Antares Pharma, INC. | $77.50 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Phathom Pharmaceuticals, INC. | $76.89 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.85 | 2020-2021 | |
| Mylan Specialty L.P. | $62.78 | 2021-2023 | Yupelri |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $40.83 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $36.94 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $32.28 | 2022-2025 | Zoryve |
| Sunovion Pharmaceuticals INC. | $31.25 | 2022 | |
| Nevro Corp. | $29.51 | 2022 | |
| Corium, LLC | $27.91 | 2025 | Azstarys |
| Halozyme INC | $27.80 | 2023 | |
| Eisai INC. | $27.52 | 2021 | |
| Biogen, INC. | $22.12 | 2024 | Skyclarys |
| Abbott Laboratories | $21.97 | 2025 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $21.81 | 2023 | Austedo Xr |
| Sumitomo Pharma America, INC. | $19.17 | 2025 | Gemtesa |
| Paratek Pharmaceuticals, INC. | $14.80 | 2024 | Nuzyra |
| Xeris Pharmaceuticals, INC. | $14.25 | 2024 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $13.08 | 2022 | |
| Axsome Therapeutics, INC. | $12.11 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Raborn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.